Market: NMS |
Currency:
Address:
๐ ORIO Historical Chart
๐ Statistics
-
Analyst 1 Year Price Target:
$2.82
-
Upside/Downside from Analyst Target:
127.52%
-
Broker Call:
3
-
Dividend Minimum 3 Year Yield:
-
-
EPS Growth Range (1Y):
25-50%
-
Net Income Growth Range (1Y):
25-50%
-
Revenue Growth Range (1Y):
0-10%
-
Upcoming Earnings Date:
-
๐ฐ Dividend History
No dividend history available.
๐
Earnings & EPS History for ORIO
No earnings history available for this symbol.
๐ฐ Related News & Research
-
Orion Energy Systems, Inc. 8-K Filing: Project Zeus Settlement Agreement and Key Entity Information (March 2026)
March 21, 2026
Orion Energy Systems, Inc. (NASDAQ: OESX) Announces Entry In...
-
Orion Group Holdings Announces Retirement of Two Board Members and Reduction in Board Size to Six Directors
March 20, 2026
Orion Group Holdings Announces Retirement of Two Board Membe...
-
Glorious Sun Enterprises Limited Announces Board Meeting to Approve 2025 Final Results and Dividend on 26 March 2026
March 11, 2026
Glorious Sun Enterprises Limited Announces Date of Board Mee...
-
Orion S.A. Announces 2026 Annual General Meeting Date and Record Date for Shareholders
March 7, 2026
Orion S.A. Announces 2026 AGM and Record Date - Investor Ins...
-
Orion Properties Inc. Reports 2025 Financial Results, Strategic Review, Leasing and Disposition Activity, and 2026 Outlook
March 6, 2026
Orion Properties Inc. Reports Q4 and Full Year 2025 Financia...
-
Orion Properties Inc. 2025 Annual Report: Business Overview, Strategy, Risk Factors, and Financial Highlights
March 5, 2026
Orion Properties Inc. 2025 Annual Report: Key Insights for I...
-
Orion Group Holdings, Inc. 2025 Annual Report โ Marine & Concrete Construction Business Overview, Strategy, Market Analysis, and Financial Highlights
March 4, 2026
Orion Group Holdings, Inc. 2025 Annual Report: Key Highlight...
-
iX Biopharma Partners with Orion to Accelerate WaferiXยฎ Commercialisation in US Market via FDA-Licensed Compounding Network
November 10, 2025
iX Biopharma Secures Strategic U.S. Partnership to Accelerat...
๐ View more Reports